Drug approval summaries: Arsenic trioxide, tamoxifen citrate, anastrazole, paclitaxel, bexarotene

Oncologist

Volumn 6, Issue 1, 2001, Pages 4-11

  Cohen, Martin H ^a   Hirschfeld, Steven ^a   Honig, Susan Flamm ^a   Ibrahim, Amna ^a   Johnson, John R ^a   O'Leary, James J ^a   White, Robert M ^a   Williams, Grant A ^a   Pazdur, Richard ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Anastrazole; Arsenic trioxide; Bexarotene; Paclitaxel; Tamoxifen citrate

Indexed keywords

ANASTROZOLE; ARSENIC TRIOXIDE; BEXAROTENE; PACLITAXEL; TAMOXIFEN CITRATE; TRISONEX; UNCLASSIFIED DRUG;

ACUTE MYELOBLASTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; BREAST CARCINOMA; CANCER COMBINATION CHEMOTHERAPY; DRUG INFORMATION; HUMAN; OVARY CANCER; PRIORITY JOURNAL; REVIEW; SKIN LYMPHOMA;

ANTICARCINOGENIC AGENTS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ARSENICALS; BREAST NEOPLASMS; DRUG APPROVAL; FEMALE; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; LYMPHOMA, T-CELL, CUTANEOUS; NITRILES; OXIDES; PACLITAXEL; TAMOXIFEN; TETRAHYDRONAPHTHALENES; TRIAZOLES; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 0035135374     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.6-1-4     Document Type: Review

References (26)

1. Pharmacokinetic properties of the trypanocidal drug melarsoprol
2. 3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients
3. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide
4. Medical progress: Acute promyelocytic leukemia
5. A clinical and experimental study on all-trans retinoic acid-treated acute promyelocytic leukemia patients
6. Therapy of acute promyelocytic leukemia: Alltrans retinoic acid and beyond
7. Ductal carcinoma in situ of the breast
8. Ductal carcinoma in situ of the breast
9. Lumpectomy compared with lumpectomy and radiation therapy for the treatment of intraductal breast cancer
10. Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) eight-year update of protocol B-17: Intraductal carcinoma
11. Predicting local recurrence in patients with ductal carcinoma in situ
12. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study
13. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomized controlled trial
14. Risks and benefits of aromatase inhibitors in postmenopausal breast cancer
15. Biology of aromatase inhibitors: Pharmacology/endocrinology within the breast
16. Use of aromatase inhibitors in breast cancer
17. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer
18. Paclitaxel delivered as a 3-hr infusion with cisplatin in patients with gynecologic cancers: Unexpected incidence of neurotoxicity
19. Phase I dose escalation of paclitaxel in patients with advanced ovarian cancer receiving cisplatin: Rapid development of neurotoxicity is dose limiting
20. Mycosis fungoides in the United States: Increasing incidence and descriptive epidemiology
21. Topical treatment of early cutaneous T-cell lymphoma
22. Experimental therapies in the treatment of cutaneous T-cell lymphoma
23. Emerging new therapies for cutaneous T-cell lymphoma
24. Current use and future potential role of retinoids in dermatology
25. Oral retinoids in mycosis fungoides and sezary syndrome: A comparison of isotretinoin and etretinate - A study from the Scandinavian Mycosis Fungoides Group
26. Initial clinical trial of a selective retinoid X receptor ligand LGD1069